Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Natural history and therapeutic options for COVID-19

IHU, Expert Review of Clinical Immunology
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Review of the current state of knowledge regarding the natural history of and therapeutic options for COVID-19.
Treatment with an oral combination of hydroxychloroquine, azithromycin and zinc may represent the best current therapeutic option in relation to its antiviral and
immunomodulatory effects.
Reviews covering hydroxychloroquine for COVID-19 include Al-Bari, Brouqui, Colson, Derwand, Gao, Goldstein, Hecel, IHU, Kaur, Li, Loo, Matada, Roussel, Sahraei, Todaro, Vigbedor.
IHU et al., 7 Sep 2020, peer-reviewed, 1 author.
This PaperHCQAll
Introduction 28 COVID-19 presents benign forms in young patients who frequently present with anosmia. 29 Infants are rarely infected, while severe forms occur in patients over 65 years of age with 30 comorbidities, including hypertension and diabetes. Lymphopenia, eosinopenia, 31 thrombopenia, increased lactate dehydrogenase, troponin, C-reactive protein, D-dimers, and 32 low zinc levels are associated with severity. 33 Areas covered 34 The authors review the literature and provide an overview of the current state of knowledge 35 regarding the natural history of and therapeutic options for COVID-19. 36 Expert opinion 37 Diagnosis should rely on PCR and not on clinical presumption. Because of discrepancies 38 between clinical symptoms, oxygen saturation or radiological signs on CT scans, pulse 39 oximetry and radiological investigation should be systematic. The disease evolves in 40 successive phases: an acute virological phase, and, in some patients, a cytokine storm phase; 41 an uncontrolled coagulopathy; and an acute respiratory distress syndrome. Therapeutic 42 options include antivirals, oxygen therapy, immunomodulators, anticoagulants and prolonged 43 mechanical treatment. Early diagnosis, care, and implementation of an antiviral treatment; the 44 use of immunomodulators at a later stage; and the quality of intensive care are critical 45 regarding mortality rates. The higher mortality observed in Western countries remains 46 unexplained. Pulmonary fibrosis may occur in some patients. Its future is unpredictable.
pulmonary embolism in our day care hospital after systematic D-dimer assessment without 717 any clinical signs. In the presence of a clinical (NEWS score ≥ 5) or biological sign of 718 severity, or if the treatment became difficult, patients were systematically hospitalized. have been observed. In the 60+ age group, the mortality regardless of treatment was 5.0%, 723 which was similar to the mortality in the same age group reported in China (6.0%) but lower 724 than that reported in Italy (12.3%) [171] . On the other hand, among patients aged 60 years and 725 over who had at least three days of dual HCQ-AZ therapy in our center, the mortality was 726 3.1%, which was much lower than that reported in China and Italy for the same age group. Supportive care No evidence of drug efficacy Quality of ICU care (respiratory support) Anti-coagulant therapy
References
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, 1253 azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect
Barbosa-Esper, Da Silva, Costa Oikawa, Azithromycin and Hydroxychloroquine Accelerate 1360 Recovery of Outpatients with Mild/Moderate COVID-19, doi:136110.20944/preprints202005.0486.v1.1362170
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 1300 -Preliminary Report, N Engl J Med
Bernaola, Mena, Bernaola, A Multicenter, randomized, open-label, controlled 1273 trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective 1274 study in adult patients with mild to moderate Coronavirus disease, MedRxiv, doi:10.1101/2020.07.17.20155960.1272
Bikdeli, Madhavan, Jimenez, COVID-19 and Thrombotic or 1367 Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and 1368 Follow-up, J Am Coll Cardiol
Boulware, Pullen, Bangdiwala, A Randomized Trial of 1347 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Bouvet, Debarnot, Imbert, In vitro reconstitution of SARS-coronavirus 1028 mRNA cap methylation, PLoS Pathog
Braun, Loyal, Frentsch, Presence of SARS-CoV-2-reactive T cells in 1063 COVID-19 patients and healthy 2 donors
Cai, Sun, Huang, Indirect Virus Transmission in Cluster of COVID-19 1023 Cases, Wenzhou, China, Emerg Infect Dis
Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized 1081 with Severe Covid-19, N Engl J Med
Carlucci, Ahuja, Petrilli, Hydroxychloroquine and azithromycin plus 1292 zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized 1293 COVID-19 patients, N Engl J Med, doi:10.1101/2020.05.02
Cassell, Edwards, Brown, Effects of lysosomotropic weak bases on infection 1186 of BHK-21 cells by Sindbis virus, J Virol
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without 1268 Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med
Channappanavar, Fehr, Vijay, Dysregulated Type I Interferon and 1092 Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-1093 CoV-Infected Mice, Cell Host Microbe
Chatterjee, Anand, Singh, Can post-exposure prophylaxis for COVID-19 be 1344 considered as an outbreak response strategy in long-term care hospitals?, Antimicrob Agents
Chen, Wu, Guo, Clinical and immunological features of severe and 1083 moderate coronavirus disease 2019, J Clin Invest
Chen, Zhang, Fu, Efficacy and safety of chloroquine or 1258 hydroxychloroquine in moderate type of COVID-19: a prospective open-label 1259 randomized controlled study
Choy, De, Takeuchi, Translating IL-6 biology into effective treatments, Nat Rev Rheumatol
Damle, Vourvahis, Wang, Clinical Pharmacology Perspectives on the 1277 Antiviral Activity of Azithromycin and Use in COVID-19, Clin Pharmacol Ther, doi:10.1101/2020.07
Devaux, Rolain, Colson, New insights on the antiviral effects of 1172 chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob
Dinarello, Interleukin-1 in the pathogenesis and treatment of inflammatory 1105 diseases, Blood
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-1409 19), Drug Discov Ther
Edouard, Colson, Melenotte, Evaluating the serological status of COVID-1070 19 patients using an indirect immunofluorescent assay, France, IHU Médirranée
Eldin, Melenotte, Mediannikov, From Q Fever to Coxiella burnetii 1398 Infection: a Paradigm Change, Clin Microbiol Rev
Engelmann, Massberg, Thrombosis as an intravascular effector of innate 1117 immunity, Nat Rev Immunol
Fantini, Di, Chahinian, Structural and molecular modelling studies reveal 1169 a new mechanism of action of chloroquine and hydroxychloroquine against SARS-1170 CoV-2 infection, Int J Antimicrob Agents, doi:10.1101/2020.03.18.997585.1168101
Feng, Diao, Wang, A study of immune responses to SARS-CoV-1050 2 in 54 patients identifying two distinct immune profiles associated with severe 1051 respiratory failure: macrophage activation syndrome and a typical immune 1052 dysregulation pattern with increased IL-6, decreased macrophage antigen 1053 presentation and hyperinflammation, Cell Mol Immunol
Fiore, Fry, Shay, Antiviral agents for the treatment and 1349 chemoprophylaxis of influenza ---recommendations of the Advisory Committee on 1350 Immunization Practices (ACIP), MMWR Recomm Rep
Fung, Liu, Coronavirus infection, ER stress, apoptosis and innate immunity, Front Microbiol
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent 1406 efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci
Garbers, Heink, Korn, Interleukin-6: designing specific therapeutics for a 1309 complex cytokine, Nat Rev Drug Discov
Gattinoni, Chiumello, Caironi, COVID-19 pneumonia: different 1373 respiratory treatments for different phenotypes?, Intensive Care Med
Gautret, Lagier, Parola, Clinical and microbiological effect of a 1286 combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with 1287 at least a six-day follow up: A pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a 1207 treatment of COVID-19: results of an open-label non-randomized clinical trial, Antimicrob Agents
Goldman, Lye, Hui, Remdesivir for 5 or 10 Days in Patients with 1302 Severe Covid-19, N Engl J Med
Gordon, Jang, Bouhaddou, A SARS-CoV-2 protein interaction map 1153 reveals targets for drug repurposing
Grifoni, Weiskopf, Ramirez, Targets of T Cell Responses to SARS-CoV-994 2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Guo, Wang, Zhang, Aerosol and Surface Distribution of Severe 1025 Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, Emerg Infect Dis
Gupta, Zhao, Evans, Connors, Levy, COVID-19 and its implications for thrombosis and 1121 anticoagulation, Thromb
Hadjadj, Yatim, Barnabei, Impaired type I interferon activity and 1041 inflammatory responses in severe COVID-19 patients, Science
Herold, Jurinovic, Amreich, Level of IL-6 predicts respiratory failure in 1087 hospitalized symptomatic COVID-19 patients
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 Cell Entry Depends 1034 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, J Thromb Haemost
Horby, Mafham, Linsell, Effect of Hydroxychloroquine in Hospitalized 1262 Patients with COVID-19: Preliminary results from a multi-centre, randomized, 1263 controlled trial, Ann Intern Med, doi:10.1101/2020.07.15
Huet, Beaussier, Voisin, Jouveshomme, Dauriat et al., Anakinra for 1332 severe forms of COVID-19: a cohort study, Lancet Rheumatol, doi:10.1016/S2665-9913(20
Kaplanski, Interleukin-18: Biological properties and role in disease pathogenesis, Immunol Rev
Kaplanski, Marin, Montero-Julian, IL-6: a regulator of the transition from 1306 neutrophil to monocyte recruitment during inflammation, Trends Immunol
Kaushik, Subramani, Anang, Zn(2+) inhibits coronavirus and 1196 arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication 1197 of these viruses in cell culture, Virol
Keyaerts, Li, Vijgen, Antiviral activity of chloroquine against human 1179 coronavirus OC43 infection in newborn mice, Antimicrob Agents Chemother
Keyaerts, Vijgen, Maes, In vitro inhibition of severe acute respiratory 1176 syndrome coronavirus by chloroquine, Biochem Biophys Res Commun
Kk, Tsang, Chik-Yan, Consistent detection of 2019 novel 1009 coronavirus in saliva, Int J Antimicrob Agents
Klok, Kruip, Van Der Meer, Incidence of thrombotic 1123 complications in critically ill ICU patients with COVID-19, Thromb Res
Kono, Tatsumi, Imai, Inhibition of human coronavirus 229E infection 1202 in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and 1203 ERK, Antiviral Res
Lippi, Favaloro, Tang, Li, Wang et al., Abnormal coagulation parameters are associated with 1114 poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, 1138 is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Liu, Sun, Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to 1011 infect respiratory tract, J Med Virol
Liu, Wei, Lin, Anti-spike IgG causes severe acute lung injury by skewing 1077 macrophage responses during acute SARS-CoV infection, JCI Insight
Long, Liu, Deng, Antibody responses to SARS-CoV-2 in patients 1068 with COVID-19, Nat Med
Lu, Zheng, Xu, Severe acute respiratory syndrome-associated 1102 coronavirus 3a protein forms an ion channel and modulates virus release, Acad Sci U S A
Mehta, Mcauley, Brown, COVID-19: consider cytokine storm 1085 syndromes and immunosuppression, Lancet
Mikami, Miyashita, Yamada, Risk Factors for Mortality in Patients with 1256 COVID-19 in New York City, J Gen Intern Med
Million, Gautret, Colson, Clinical Efficacy of Chloroquine Derivatives in 1210 COVID-19 Infection: Comparative Meta-analysis between the Big Data and the Real 1211, World. New Microbes and New Infection
Million, Lagier, Gautret, Early treatment of COVID-19 patients with 1283 hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in 1284 Marseille, France, Travel Med Infect Dis
Mo, Fisher, A review of treatment modalities for Middle East Respiratory 1182 Syndrome, J Antimicrob Chemother
Ng, Faulkner, Cornish, Analysis of SARS-CoV-2 Antibodies in 1002 COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray, bioRxiv, doi:10.1101/2020.05.14.095414
Ni, Ye, Cheng, Detection of SARS-CoV-2-Specific Humoral and 1074 Cellular Immunity in COVID-19 Convalescent Individuals, Immunity
Nicastri, Petrosillo, Bartoli, IRCCS. Recommendations for COVID-19 clinical management, Infect Dis Rep
Onder, Rezza, Brusaferro, Case-Fatality Rate and Characteristics of Patients 1365 Dying in Relation to COVID-19 in Italy, JAMA
Peng, Liu, Xu, SARS-CoV-2 can be detected in urine, blood, anal swabs, 1013 and oropharyngeal swabs specimens, J Med Virol
Perlman, Netland, Coronaviruses post-SARS: update on replication and 1032 pathogenesis, Nat Rev Microbiol
Perrier, Bonnin, Desmarets, The C-terminal domain of the MERS 1199 coronavirus M protein contains a trans-Golgi network localization signal, J Biol Chem
Pizzorno, Padey, Dubois, Hydroxychloroquine in patients with mainly mild to 1403 moderate coronavirus disease 2019: open label, randomised controlled trial, Antiviral Res
Platt, Association of Treatment With 1216 Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With 1217 COVID-19 in New York State, N Engl J Med, doi:10.1016/j.nmni.2020.100709.1213118
Poissy, Goutay, Caplan, Pulmonary Embolism in COVID-19 Patients: 1126 Awareness of an Increased Prevalence, Circulation
Raoult, Million, Gautret, Hydroxychloroquine and Azithromycin as a 1249 Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: 1250 Response to David Spencer, IHU Preprints, doi:10.35088/bjjr-cy47
Richardson, Hirsch, Narasimhan, Presenting Characteristics, 1370 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in 1371 the, JAMA
Rothe, Schunk, Sothmann, Transmission of 2019-nCoV Infection from an 1019 Asymptomatic Contact in Germany, N Engl J Med
Savarino, Boelaert, Cassone, Effects of chloroquine on viral infections: 1205 an old drug against today's diseases?, Lancet Infect Dis
Shah, Modi, Sagar, Choudary, Malik et al., In silico studies on therapeutic agents for COVID-19: 1160 Drug repurposing approach, doi:116110.1016/j.lfs.2020.117652.:117652.116299
Shi, Nabar, Huang, SARS-Coronavirus Open Reading Frame-8b 1097 triggers intracellular stress pathways and activates NLRP3 inflammasomes, Trends Immunol
Singh, Khan, Chowdhry, Chatterjee, Narendran et al., Outcomes of Hydroxychloroquine 1219 Treatment Among Hospitalized COVID-19 Patients in the United States-Real-World 1220 Evidence From a Federated Electronic Medical Record Network, Centers for Disease Control and Prevention, doi:10.1101/2020.05.12
Slaats, Ten, Van De Veerdonk, IL-1β/IL-6/CRP and IL-18/ferritin: 1109 Distinct Inflammatory Programs in Infections, PLoS Pathog
Tay, Poh, Rénia, A Sequence Homology and Bioinformatic 1060 Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2, Cell Host Microbe
Touret, De, Of chloroquine and COVID-19, Antiviral Res
Touret, Gilles, Barral, In vitro screening of a FDA approved chemical 1147 library reveals potential inhibitors of SARS-CoV-2 replication, Microb Pathog, doi:10.1101/2020.04.03.023846
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS 1184 coronavirus infection and spread, Virol J
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the 1136 recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Chen, Liu, Anticoagulant treatment is associated with decreased 1130 mortality in severe coronavirus disease 2019 patients with coagulopathy, Lancet Haematol
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a 1297 randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Weston, Coleman, Haupt, Broad anti-coronaviral activity of FDA 1140 approved drugs against 2 SARS-CoV-2 in vitro and SARS-CoV in vivo, bioRxiv, doi:10.1101/2020.03.25.008482
Wu, Tak-Yin, To, Cross-reactive antibody response between SARS-1066 CoV-2 and SARS-CoV infections, Cell Rep, doi:10.1101/2020.04.17.20061440.t.1065
Wu, Wang, Liu, Neutralizing antibody responses to SARS-CoV-2 in a 1039 COVID-19 recovered patient cohort and their implications
Xu, Shi, Wang, Pathological findings of COVID-19 associated with acute 1043 respiratory distress syndrome, Lancet Respir Med
Xue, Moyer, Peng, Chloroquine is a zinc ionophore, PLoS ONE
Yang, Huang, Ganesh, pH-dependent entry of severe acute respiratory 1188 syndrome coronavirus is mediated by the spike glycoprotein and enhanced by 1189 dendritic cell transfer through DC-SIGN, J Virol
Yao, Ye, Zhang, In Vitro Antiviral Activity and Projection of Optimized 1133 Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory 1134 Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Yu, Li, Chen, Low dose of hydroxychloroquine reduces fatality of 1339 critically ill patients with COVID-19, Sci China Life Sci
Yue, Nabar, Shi, SARS-Coronavirus Open Reading Frame-3a drives 1090 multimodal necrotic cell death, Cell Death Dis, doi:10.1101/2020.04.01.20047381.1089
Zalinger, Elliott, Weiss, Role of the inflammasome-related cytokines Il-1 1095 and Il-18 during infection with murine coronavirus, J Neurovirol
Zhai, Ding, Wu, The epidemiology, diagnosis and treatment of COVID
Zhang, Ma, Yu, The FDA-approved drug ivermectin inhibits the 1145 replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1101/2020.02.05.935387
Zhang, Xiao, Zhang, Coagulopathy and Antiphospholipid Antibodies in 1079 Patients with Covid-19, N Engl J Med
Zimmermann, Ziesenitz, Curtis, The Immunomodulatory Effects of 1280 Macrolides-A Systematic Review of the Underlying Mechanisms, Front Immunol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit